Ovid Therapeutics Inc (OVID) - Net Assets
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has net assets worth $44.70 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.85 Million) and total liabilities ($19.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OVID cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $44.70 Million |
| % of Total Assets | 70.01% |
| Annual Growth Rate | 30.56% |
| 5-Year Change | 56.37% |
| 10-Year Change | 0.23% |
| Growth Volatility | 405.87 |
Ovid Therapeutics Inc - Net Assets Trend (2014–2024)
This chart illustrates how Ovid Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore OVID total assets for the complete picture of this company's asset base.
Annual Net Assets for Ovid Therapeutics Inc (2014–2024)
The table below shows the annual net assets of Ovid Therapeutics Inc from 2014 to 2024. For live valuation and market cap data, see OVID market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $68.23 Million | -22.29% |
| 2023-12-31 | $87.80 Million | -33.62% |
| 2022-12-31 | $132.27 Million | -26.41% |
| 2021-12-31 | $179.75 Million | +311.96% |
| 2020-12-31 | $43.63 Million | -37.69% |
| 2019-12-31 | $70.02 Million | +80.45% |
| 2018-12-31 | $38.81 Million | -53.49% |
| 2017-12-31 | $83.44 Million | +69.26% |
| 2016-12-31 | $49.29 Million | -27.58% |
| 2015-12-31 | $68.07 Million | +1336.58% |
| 2014-12-31 | $4.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ovid Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30396383100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $71.00K | 0.10% |
| Other Comprehensive Income | $-35.00K | -0.05% |
| Other Components | $372.49 Million | 545.96% |
| Total Equity | $68.23 Million | 100.00% |
Ovid Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Ovid Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fima Corporation Bhd
KLSE:3107
|
$101.13 Million |
|
Tai Tung Communication Co Ltd
TW:8011
|
$101.15 Million |
|
eGalax_eMPIA Technology
TWO:3556
|
$101.15 Million |
|
Han Shin Mach
KO:011700
|
$101.16 Million |
|
Ching Feng Home Fashions Co Ltd
TW:9935
|
$101.10 Million |
|
Simpac
KO:009160
|
$101.09 Million |
|
Hispanotels Inversiones SOCIMI SA
MC:YHSP
|
$101.07 Million |
|
FCW Holdings Bhd
KLSE:2755
|
$101.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ovid Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 87,797,000 to 68,226,000, a change of -19,571,000 (-22.3%).
- Net loss of 26,433,000 reduced equity.
- Other comprehensive income decreased equity by 35,702.
- Other factors increased equity by 6,897,702.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.43 Million | -38.74% |
| Other Comprehensive Income | $-35.70K | -0.05% |
| Other Changes | $6.90 Million | +10.11% |
| Total Change | $- | -22.29% |
Book Value vs Market Value Analysis
This analysis compares Ovid Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.80x to 2.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $1.00 | $2.79 | x |
| 2015-12-31 | $3.47 | $2.79 | x |
| 2016-12-31 | $2.51 | $2.79 | x |
| 2017-12-31 | $4.31 | $2.79 | x |
| 2018-12-31 | $1.58 | $2.79 | x |
| 2019-12-31 | $1.79 | $2.79 | x |
| 2020-12-31 | $0.75 | $2.79 | x |
| 2021-12-31 | $2.64 | $2.79 | x |
| 2022-12-31 | $1.88 | $2.79 | x |
| 2023-12-31 | $1.24 | $2.79 | x |
| 2024-12-31 | $0.96 | $2.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ovid Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4670.14%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.35x
- Recent ROE (-38.74%) is above the historical average (-56.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -9.43% | 0.00% | 0.00x | 1.03x | $-920.81K |
| 2015 | -19.33% | 0.00% | 0.00x | 1.03x | $-19.97 Million |
| 2016 | -45.47% | 0.00% | 0.00x | 1.08x | $-27.34 Million |
| 2017 | -77.67% | 0.00% | 0.00x | 1.07x | $-73.15 Million |
| 2018 | -133.95% | 0.00% | 0.00x | 1.23x | $-55.86 Million |
| 2019 | -84.63% | 0.00% | 0.00x | 1.15x | $-66.26 Million |
| 2020 | -185.02% | -639.83% | 0.17x | 1.74x | $-85.09 Million |
| 2021 | 68.34% | 58.95% | 1.07x | 1.08x | $104.86 Million |
| 2022 | -38.87% | -3420.95% | 0.01x | 1.17x | $-64.64 Million |
| 2023 | -59.61% | -13351.79% | 0.00x | 1.64x | $-61.12 Million |
| 2024 | -38.74% | -4670.14% | 0.01x | 1.35x | $-33.26 Million |
Industry Comparison
This section compares Ovid Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ovid Therapeutics Inc (OVID) | $44.70 Million | -9.43% | 0.43x | $101.12 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more